Results 11 to 20 of about 268,751 (268)

Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma.

Blood Advances, 2021
Zanubrutinib, a highly selective Bruton tyrosine kinase inhibitor, was evaluated in a phase 1/2 study in patients with various B-cell malignancies. In the subgroup of patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), zanubrutinib was ...
C. Tam, Stephen Samuel Opat, D. Simpson, G. Cull, J. Muñoz, T. Phillips, W. Kim, S. Rule, S. Atwal, R. Wei, W. Novotny, Jane E. Huang, Michael L. Wang, J. Trotman   +13 more
semanticscholar   +1 more source

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.

New England Journal of Medicine, 2020
BACKGROUND Patients with relapsed or refractory mantle-cell lymphoma who have disease progression during or after the receipt of Bruton's tyrosine kinase (BTK) inhibitor therapy have a poor prognosis. KTE-X19, an anti-CD19 chimeric antigen receptor (CAR)
Michael L. Wang, J. Muñoz, A. Goy, F. Locke, C. Jacobson, B. Hill, J. Timmerman, H. Holmes, S. Jaglowski, I. Flinn, P. Mcsweeney, D. Miklos, J. Pagel, M. Kersten, N. Milpied, H. Fung, M. Topp, R. Houot, A. Beitinjaneh, W. Peng, Lianqing Zheng, J. Rossi, R. Jain, A. Rao, P. Reagan   +24 more
semanticscholar   +1 more source

Case report: Composite mantle cell lymphoma and classical Hodgkin lymphoma

Pathology and Oncology Research, 2023
Composite mantle cell lymphoma and classical Hodgkin lymphoma is very rare and the actual origin of it is still unclear. Here we reported a new case of composite mantle cell lymphoma and classical Hodgkin lymphoma and analyzed its molecular changes ...
Hongyu Wang, Liqun Yang, Qiuyao Li, Haiyun Song, Hong Ji   +4 more
doaj   +1 more source

Mantle cell lymphoma – advances in molecular biology, prognostication and treatment approaches

British Journal of Haematology, 2021
Mantle cell lymphoma (MCL) is clinically characterised by its heterogenous behaviour with courses ranging from indolent cases that do not require therapy for years to highly aggressive MCL with a very limited prognosis.
E. Silkenstedt, K. Linton, M. Dreyling
semanticscholar   +1 more source

Mantle cell lymphoma

Blood Reviews, 1994
The term mantle cell lymphoma (MCL) has been introduced recently, to describe lymphomas related to the primary B follicle and the mantle of the secondary lymphoid follicle. MCL forms a subset of diffuse small cleaved cell lymphomas according to the Working Formulation and correspond closely to the centrocytic lymphomas described in the Kiel ...
Stefania Pittaluga, C De Wolf-Peeters
  +9 more sources

Bilateral vision loss as the initial presentation for central nervous system involvement of mantle cell lymphoma: A case series

American Journal of Ophthalmology Case Reports, 2021
Purpose: Mantle cell lymphoma is a rare aggressive subtype of non-Hodgkins B cell lymphoma. It typically presents with asymptomatic monoclonal lymphocytosis, lymphadenopathy or bulky extranodal disease.
L. Small, C. Ma, M. Shah, S. Ramanathan, N. Rasool   +4 more
doaj   +1 more source

Mantle Cell Lymphoma [PDF]

Hématologie, 2018
Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma, which is characterized by the chromosomal translocation t(11;14)(q13;q32) and overexpression of cyclin D1 in the vast majority of cases.
Milena Kohn, Lucile Bussot
  +9 more sources

Mantle cell lymphoma presenting with severe upper gastrointestinal bleeding

Medicine, 2022
. Introduction:. Although it usually involves extranodal sites such as the gastrointestinal tract in more than 80% of cases, mantle cell lymphoma is considered a rare cause of gastrointestinal bleeding, especially severe and life-threatening bleeding ...
Khaled Ali, MD, Mhd Baraa Habib, MD, Ferial Alloush, MBBS, Mohamed A. Yassin, MBBS, CABM, MSC, FACP, MSC   +3 more
doaj   +1 more source

Genomic and epigenomic insights into the origin, pathogenesis and clinical behavior of mantle cell lymphoma subtypes.

Blood, 2020
Mantle cell lymphoma (MCL) is a mature B-cell neoplasm initially driven by CCND1 rearrangement with two molecular subtypes, conventional (cMCL) and leukemic non-nodal (nnMCL), that differ in their clinicobiological behavior.
F. Nadeu, D. Martín-García, G. Clot, A. Díaz-Navarro, M. Duran-Ferrer, A. Navarro, Roser Vilarrasa-Blasi, M. Kulis, R. Royo, J. Gutiérrez-Abril, R. Valdés-Mas, C. López, V. Chapaprieta, Montserrat Puiggrós, G. Castellano, D. Costa, M. Aymerich, P. Jares, B. Espinet, A. Muntañola, Inmaculada Ribera‐Cortada, R. Siebert, D. Colomer, D. Torrents, E. Giné, A. López-Guillermo, R. Küppers, J. Martín-Subero, X. Puente, S. Beá, E. Campo   +30 more
semanticscholar   +1 more source

Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor κB pathways

Haematologica, 2012
Background There is increasing evidence that stromal cell interactions are required for the survival and drug resistance of several types of B-cell malignancies.
Daniel J. Medina, Lauri Goodell, John Glod, Céline Gélinas, Arnold B. Rabson, Roger K. Strair   +5 more
doaj   +1 more source